GlucoTrack unit Lōkahi Therapeutics starts GMP manufacturing for LT-100 osteoarthritis pain candidate
GCTK•Trial design and enrollment timeline
The program targets a shift to one subcutaneous injection per visit from 15 intradermal injections used in earlier efficacy trials.
First patient enrollment is expected later this year, subject to manufacturing completion, quality reviews, clinical readiness, and regulatory review.
GMP manufacturing campaign begins for LT-100
Lōkahi Therapeutics, a GlucoTrack subsidiary, began an initial GMP manufacturing campaign for LT-100, a pure honeybee venom biologic for knee osteoarthritis pain.
Clinical trial supply is intended to support the next clinical and regulatory milestones for LT-100.
